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Abstract

Arthritis is a very common chronic debilitating disease in people and dogs alike.
It does not discriminate based on species, and one in five dogs suffer from osteoarthritis.
The purpose of this study was to evaluate the safety and anti-arthritic efficacy of a
nutraceutical, Flex Choice, in moderately arthritic canines. Five moderately arthritic
canines that weighed between 40-65 pounds were selected for this study. Moderate
arthritis was considered a ranking of 4-6 on a scale of 1-10 with 1 being no/minimal pain
and 10 being severe and constant pain. All five canines were orally administered one Flex
Choice soft chew twice a day for 150 days. There was no control group due to limited
population. Day 0 baseline results were used as the control. On days 0, 30, 60, 90, 120,
and 150 of the study, the canines were evaluated for overall joint pain, pain during limb
manipulation, and pain after physical exertion. Radiographs were also performed on days
0 and 150 to observe if osteophyte formation may have been reduced. Serum chemistry
analysis was performed each month as well to see if Flex Choice had any adverse effects
on kidney, liver, or heart function. Body weight, heart rate, respiration rate, and
temperature were also evaluated throughout the entire study.
Treated canines had a significant reduction in overall pain levels, pain during limb
manipulation, and pain after physical exertion at some point during the study with P <
0.05. Serum chemistry indicated no significant side effects to vital organs throughout the
entire study. Heart rate, body weight, respiration rate, and temperature were not
significantly affected by the administration of Flex Choice chews. This study proves that
Flex Choice is a safe and effective way to reduce pain and inflammation associated with
canine osteoarthritis and may provide alternatives to NSAIDs.
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Chapter I: Introduction

Arthritis is a chronic, painful disease that affects many humans and targets joints
such as the wrist, hip and knee. Just like humans, dogs and other animals can be affected
by this disease. There is no cure for arthritis, but veterinarians can perform surgeries and
prescribe pharmaceuticals or nutraceuticals to help improve the joint’s flexibility and to
help reduce pain (Arthritis in Dogs, n.d.).
Osteoarthritis is the most common type or arthritis in dogs. Osteoarthritis, which
is also commonly known as degenerative joint disease, is a debilitating disease that
affects one in five dogs (Arthritis in Dogs, n.d.). Osteoarthritis can be either one of two
types of arthritis: primary or secondary. Primary osteoarthritis is a condition in which
cartilage in the joint degenerates as the dog ages. Secondary osteoarthritis occurs
secondary to joint disease, instability of the joint, or abnormal pressure on cartilage in the
joint (Texas A&M Veterinary Medicine & Biomedical Sciences, 2016).
Although osteoarthritis is not breed, age, or sex specific, there may be
predisposing factors. Senior dogs tend to be more prone to developing arthritis as they
age (Innes, 1995). Dogs who are overweight are more prone to arthritis due to increased
impact on joints. Other factors, including genetics and injuries, may make some dogs
more prone to arthritis than others (American College of Veterinary Surgeons, n.d.).
Symptoms of arthritis in dogs include activity impairment and pain. Dogs who
are suffering from osteoarthritis may not exercise as much as they once did, or they may
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have a harder time getting up or lying down. They may also experience depression and
sleep more than they used to. In order to properly diagnose osteoarthritis, a veterinarian
will perform a physical exam to assess joint mobility and pain and radiographs are used
to determine the extent of damage to joints caused by arthritis (American College of
Veterinary Surgeons, n.d.).
Since there is no cure for this disease, veterinarians do their best to make the dogs
more comfortable. Weight management and exercise are common practices in managing
arthritis in dogs. Exercise helps loosen stiff joints and helps dogs shed the extra pounds
that are adding more stress to joints. Non-steroidal anti-inflammatories (NSAIDs) are a
commonly prescribed medication to arthritic dogs. A disadvantage to NSAIDs is they
eliminate pain associated with the joint damage caused by arthritis, but do not reverse
damage and can produce side effects if given long term. Nutraceuticals are becoming
more popular because they not only help with pain associated with arthritis, but they
consist of ingredients found in cartilage, therefore promoting healthy joints and
preventing further damage (Arthritis in Dogs, n.d.).
Statement of the Problem
According to literature, one in five dogs suffer from osteoarthritis and that use of
certain pain management drugs, such as NSAIDs, may do more harm than good (Arthritis
in Dogs, n.d.). A new nutraceutical, Flex Choice, was tested for efficacy and safety in this
project.
Purpose
The purpose of this study was to determine anti-arthritic efficacy and safety of
Flex Choice in moderately osteoarthritic dogs. A comparison of pain assessment,
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radiography, physical examination, and blood tests was used by the researcher to test
efficacy and safety of the nutraceutical. This multi-method study was composed of three
major components. Assessment of pain was the first component. This was measured
using a standardized scale and a physical exam was performed to help determine level of
pain. Additionally, blood tests including chemistry panels, complete blood counts (CBC),
and erythrocyte sedimentation rate (ESR) were used to assess the effects Flex Choice had
on the body. Finally, radiographs were taken to compare the effects of Flex Choice on
selected joints.
Hypothesis
H0: (Null) There will not be a clinically significant difference in canines treated with
Flex Choice.
H1: (Research hypothesis) Canines treated with Flex Choice will have a clinically
significant reduction in pain.
Objective
The research study was guided by the following objectives:
1. Determine anti-arthritic efficacy of the nutraceutical, Flex Choice, in moderately
arthritic canines through subjective data, such as overall pain, pain after limb
manipulation and pain after physical exertion.
2. Determine safety and tolerability of the nutraceutical, Flex Choice, in moderately
arthritic canines through evaluation of objective data, such as heart rate, respiration
rate, temperature, and serum chemistry values.
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Definition of Terms
1. Osteoarthritis- the most common form of arthritis. It is caused by the wear and
tear of a joint and gradually worsens over time (Center for Disease Control and
Prevention, 2018).
2. Joint- Any point in which two or more bones are in contact (Pasquini et al., 2007).
3. Moderate Arthritis- the level of arthritis in which overall pain is described as a 4-6
on a scale of 0-10. Cartilage is compressed/damaged, and the bone becomes
thickened. Exercise is painful for moderately arthritic dogs (Gupta et al., 2011).
4. Nutraceutical- a constituent of food that is used for human and animal health
benefits for treating and preventing disease
5. Flex Choice- a nutraceutical that is being tested in this study. It is composed of
krill oil, hyaluronic acid, astaxanthin, Boswellia serrata extract, green lipped
mussel, and iron transport tocopheryl polyethylene glycol succinate (ITPGS).
6. NSAID (non-steroidal anti-inflammatory drug)- a class of drug that is commonly
given to arthritic animals to reduce inflammation and pain in joints (Innes, 1995).
7. Pain- an unpleasant sensation that is conveyed to the brain through sensory
neurons. The physical discomfort may lead to evasive action and cause injury
(Gupta et al., 2011).
8. Cartilage- a fibrous connective tissue that is found at the end of bones in the joints
that reduces friction and absorbs shock (Pasquini et al., 2007).
Limitations
This research was restricted by the following limitations:
1. The study was limited to dogs between 35 and 65 pounds.
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2. The study was limited to 5 dogs that were considered to be moderately arthritic
(overall pain of 4-6 on a scale of 0-10).
3. The study was limited to the use of Flex Choice only.
4. The study did not evaluate the effects of Flex Choice on dogs of different ages, sexes,
or breeds.
5. The study did not attempt to prove that Flex Choice cures arthritis.
6. The study was limited to 150 days.
Assumptions
The following assumptions concerning this study were made:
1. The dogs’ owners would follow directions and give Flex Choice as instructed.
2. All dogs were not given any pain medication or treatments for arthritis for two weeks
prior to the start of the study.
3. All dogs were free of any serious health conditions such as hepatic, renal, or heart
disease or failure.
4. All owners would be honest in their assessment and accurately record the dogs’ daily
pain level.
5. Differences of age, breed, sex, diet, and lifestyle would have no effect on the efficacy
of Flex Choice.
Statement of Significance
A study to determine the efficacy and safety of new nutraceuticals such as Flex
Choice, is important for a couple of reasons. First, if a nutraceutical is proven effective,
then many dogs may receive relief from this debilitating disease of osteoarthritis. Second,
if a nutraceutical is proven safe, there will be more, safer alternatives to invasive or
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noninvasive treatments for osteoarthritis. Flex Choice is not intended to cure arthritis, but
if proven effective, it will give relief to dogs who suffer from this disease and give
owners a peace of mind that they are helping their dogs stay comfortable.
Chapter Summary
Arthritis does not discriminate, but through an understanding of canine
osteoarthritis and treatments available, it is confirmed that more alternative measures are
needed. In this particular study, it is predicted that Flex Choice will reduce pain and
discomfort associated with canine arthritis. There are limitations on weight, duration,
sample size and assumptions relying on owner compliance are present, but the researcher
can draw significant conclusions based on subjective and objective parameters.
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Chapter II: Review of Literature

Introduction
The purpose of this chapter is to establish the background of osteoarthritis in
canines and the need for more management options. Literature and research available for
osteoarthritis in dogs is vast and many researchers are looking for new ways to treat and
manage the disease and pain in affected canines. Topics covered in this literature review
were osteoarthritis in canines, joint function and anatomy, and treatment options.
Osteoarthritis in Canines
Osteoarthritis is a degenerative joint disease that affects dogs and humans, along
with all mammals. Osteoarthritis is highly prevalent in adult dogs with more than 20%
affected. There is no known predisposing factor to osteoarthritis, however, genetics, age,
breed, and systemic changes such as hormones and disease have been shown to cause
increased susceptibility. This disease is a very painful, inflammatory degenerative joint
disease that affects synovial joints including the knee, elbow, hock and stifle. Although
this disease is slow to progress, it will eventually lead to loss of mobility (Comblain, et
al, 2015).
Although osteoarthritis may be defined in many ways, the American Academy of
Orthopedic Surgeons defines osteoarthritis as:
“Osteoarthritic diseases are the result of mechanical and biologic
events that destabilize normal coupling of degradation and
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synthesis of articular cartilage chondrocytes, extracellular matrix
and subchondral bone.” (Budsberg & Bartges, 2006)
Some initiating factors of osteoarthritis include aberrant repair, degeneration of articular
cartilage, formation of new bone at the articular margins, sclerosis of subchondral bone
and low-grade synovial inflammations (Innes, 1995). These initiating factors, along with
the American Academy of Orthopedic Surgeons’ definition, explain that osteoarthritis is
caused by the breakdown of cartilage and formation of new bone in its place. This causes
bone on bone action in joints and leads to pain.
Currently, there are three types of osteoarthritis: primary, secondary, and erosive
osteoarthritis (Innes, 1995). Primary osteoarthritis, also known as idiopathic, has
unidentified initiating factors. This type also symmetrically affects joints and can affect
the knees, elbows, hocks, stifles, or any combination as long as joints on both sides (left
and right limb) are affected. Primary osteoarthritis is not very common in dogs but has
been documented in young adult dogs of the Chow Chow, Dalmatian, Samoyed,
Labrador Retriever, and Spaniel breeds. Secondary osteoarthritis is the most common
type and usually has an identifiable cause (Innes, 1995). Some causes of secondary
osteoarthritis include trauma, development issues, inflammatory joint disease, or
metabolic disease. Erosive, or atrophic, osteoarthritis is the third type of osteoarthritis.
This type is not well documented in dogs, but it may occasionally be detected by erosive
changes upon radiography (Innes, 1995).
Diagnosing osteoarthritis can be difficult since many owners do not seek
veterinary care until major joint degradation has already occurred or it is brought up in
conversation at annual vet visits. A history of the patient and examination of the clinical
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signs is necessary to diagnose osteoarthritis. Signs of osteoarthritis include chronic
lameness, stiffness, decreased range of motion, and a thickened joint upon palpation, as
well as the presence of crepitation (Merck, 2016). Joint thickening is caused by capsular
fibrosis and osteophyte production. Other than evaluation of clinical signs, radiographs
may be taken to visualize joints and see the extent of osteoarthritis. Arthrocentesis may
also be performed to evaluate synovial fluid color and viscosity (Innes, 1995).
Since osteoarthritis is caused by pathological changes in articular cartilage, there
is no known cure. Pain management measures are the only option in affected animals
(Innes et al., 2010). There are several forms of pain management that range from invasive
to non-invasive.
Joint Function and Anatomy
Joints are an important part of an animal’s body. Joints work together with bones,
tendons, and ligaments to allow an animal to move. Synovial joints are the joints most
commonly affected by osteoarthritis. They are diarthrodial, movable joints that are
characterized by mobility, joint cavity, articular cartilage, synovial membrane, and a
fibrous capsule (Pasquini et al., 2007).
Joint capsules are a two layered structure that surround joints and are composed
of an outer fibrous layer and an inner synovial membrane. Fibrous layers attach to
periosteum on or near margins of the articular cartilage and synovial membranes are
highly vascular, nerve rich membranes that produce synovial fluid for joints. Synovial
fluid has the consistency of a raw egg white and lubricates joints. It helps supply nutrients
to joints and removes waste products. Articular cartilage covers ends of bones and helps
to reduce friction and concussion. Ligaments are bands of fibrous connective tissue that
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connect bone to bone. They help keep everything together but still allow for movement
(Pasquini et al., 2007). Tendons are connective tissue that connect muscle to bone.
Synovial joints are called freely movable joints because they can move in
different ways depending on what classification they are. Simple joints have two articular
surfaces enclosed in a joint capsule while a compound joint has more than two. There are
also plane joints that glide, ball-and-socket joints that have a head fitting into a pit, a
hinge joint that can either increase or decrease the angles between bones, pivot joints that
allow rotation, and ellipsoidal joints that are convex/concave (Pasquini et al., 2007).
These are all types of synovial joints that allow the body to move and can be affected by
osteoarthritis.
Treatment Options for Osteoarthritis
Canine osteoarthritis is a very painful disease that requires treatment to keep
animals comfortable. Without some form of pain management, quality of life will be
diminished. Fortunately, there are many ways to manage the pain associated with
osteoarthritis, although precautions must be taken as some are not without adverse side
effects. Some options for treatment include physical therapy, weight management,
surgery, medications, and nutraceuticals.
Physical Therapy and Weight Management
Since osteoarthritis is a joint disease, mobility may be decreased as the disease
progresses. It is important to keep dogs with osteoarthritis physically active to keep joints
moving and at an adequate weight to prevent unnecessary force on joints. It is also
important to monitor these dogs regularly to ensure they are maintaining movement and
not gaining weight. (McKee, 2013). Use of a body condition score to monitor weight is
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strongly advised when this method of arthritis management is selected. This method may
also be used in conjunction with medication or a nutraceutical.
Obesity is described as accumulation of excess body fat and increased body
weight causes excess pressure on joints and cartilage, causing more pain and degradation.
Adipose tissue, or fat, is considered metabolically active and proinflammatory which
leads to more inflammation in joints (Budsberg & Bartges, 2006). It is important to keep
the animal active. Short walks with adequate rest in between are all that is needed.
Surgery
Surgery is usually the last resort for dogs with osteoarthritis unless it is secondary
to an underlying cause. There are only three instances when surgery would be warranted:
a) to treat underlying causes, b) as an attempt to treat osteoarthritis, or c) to remove or
replace an osteoarthritic joint (Innes, 1995). There are surgeries that may be performed
on any joint that can be affected by osteoarthritis. Common surgeries are a cheilectomy
(removal of osteophytes), articular forage (drilling across metaphyseal scars), excision
arthroplasty, joint replacement, and arthrodesis (fusion of joints) (Innes, 1995; Mckee,
2013).
Medications and Nutraceuticals
There are a few medications available that can be used for managing pain caused
by osteoarthritis. There are two classes of drugs that are commonly administered: nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Nutraceuticals are also
another option rising in popularity.
Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of drug that are
considered a mainstay in pain management as they are an analgesic as well as an anti-
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inflammatory. These drugs relieve clinical signs associated with osteoarthritis without a
myriad of potential metabolic and immunosuppressive adverse effects that are commonly
associated with corticosteroids (Merck, 2016). NSAIDs act primarily to reduce
biosynthesis of prostaglandins by inhibiting cyclooxygenase (COX). There are two
different isoforms of COX that have been discovered (COX-1 and COX-2) and this
discovery has led to a greater understanding of the mode of action and adverse effects of
NSAIDs. COX-1 is found in most body tissues and is responsible for mediating a variety
of normal physiological effects. This includes hemostasis, GI mucosal protection and
protection of the kidney from hypotensive insult. COX-2 is activated in damaged and
inflamed tissues and also catalyzes the formation of prostaglandin, which is associated
with inflammatory response. One downside to use of NSAIDs is that they cannot
differentiate between the two isoforms of COX, inhibiting positive COX-1 enzymes. This
contributes to common side effects often seen with use of NSAIDs (Merck, 2016).
Commonly used NSAIDs include Carprofen, Metacam, Previcox, and others. All
NSAIDs have the potential to induce adverse effects, including vomiting, gastritis and
ulceration. GI blood loss may occur and result in iron-deficient anemia. Nephropathies
and hepatopathies have also been recognized with long term used of NSAIDs (Merck,
2016). NSAIDs may be used short or long term. However, use must be monitored with
regular blood work to ensure that organ function is not compromised.
Corticosteroids are another class of drug used to manage pain associated with
osteoarthritis. Glucocorticoids are the most common corticosteroids used.
Glucocorticoids suppress inflammatory responses by interacting with specific
intracellular receptor proteins in target tissues. Results of the end process include blocked
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synthesis of prostaglandins, inhibited production of COX enzymes, cytokines, and
enzymes such as collagenases and aggrecanases. Adverse effects of corticosteroid use
include polyuria, polydipsia, suppressed immune system, hepatopathy, and reduced
collagen synthesis (Merck, 2016). Corticosteroids were once commonly used to treat
osteoarthritis, but NSAIDs have now become a popular treatment.
Nutraceuticals are natural supplements that have been shown to reduce
osteoarthritis effects in dogs. They can be used individually or in combination to form a
supplement in which effects of each compound are combined to reach a desired effect.
Nutraceuticals are becoming a popular alternative to other medications such as NSAIDs,
as they have little to no side effects and are able to lessen pain and discomfort that is
associated with canine arthritis. There are many different nutraceuticals on the market
and more are being added regularly due to the increase in popularity. One of the more
recently introduced nutraceuticals is Flex Choice.
Flex Choice
Flex Choice is categorized as a nutraceutical and was chosen for this study based
on its analgesic and anti-inflammatory properties. Flex Choice is a joint supplement that
is composed of krill oil, hyaluronic acid, astaxanthin, Boswellia serrata extract, green
lipped mussel, and iron transport tocopheryl polyethylene glycol succinate (ITPGS).
Krill oil is a source of Omega-3 fatty acids and has been found as a source of
phospholipids and antioxidants. Omega-3 fatty acids are polyunsaturated fatty acids
(PUFAs) and are beneficial for treatment of canine osteoarthritis. Fish oils, including krill
oil, are excellent sources of two out of three types of omega-3 fatty acids involved in
mammalian systems: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
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Omega-3 fatty acids act by reducing IL-1β, PGE2, ADAMTS-4, COX-2, IL-1α, iNOS,
TNF-α, MMP-3, MMP-13, and aggrecanase and collagenase activities, as well as by
increasing collagen synthesis. EPA is the most effective type of omega-3, followed by
DHA. PUFAs have a way to protect activation of autophagy in chondrocytes by
modulating mammalian targets of rapamycin (mTOR) signaling, therefore making them
an effective way of treating osteoarthritis (Gupta et al, 2019).
Hyaluronic acid (HA) is an anionic, nonsulfated glycosaminoglycan (GAG) that
is produced by chondrocytes and synovial fibroblasts. HA is an important compound in
articular cartilage as it coats each chondrocyte. HA size decreases with age but increases
in volume. It has been shown that treatment with HA of higher molecular weight is more
effective. There are two common methods of administering HA: intra-articularly (IA) and
orally. IA treatment with HA has been used for decades as a therapy for osteoarthritis in
horses and canines. In this method, HA is injected directly into affected joints. Oral
administration of high molecular weight HA has been proven to also reach joints, making
it a justified route of supplementation. There is a third method of administration,
intravenous, but it has not gained popularity and has only been tested in horses. HA is
effective at treating osteoarthritis as it may have a role in regulating synthesis of
proteoglycans during maturation of articular cartilage. It may also play a role in repair
processes of articular joints. HA works by mitigating activities of pro-inflammatory
mediators and pain-producing neuropeptides that are released by activated synovial cells.
HA can also reduce nerve impulses and sensitivity that is associated with pain from
osteoarthritis. In osteoarthritis, treatment is usually the only option for management, but
studies have shown that HA prevents degradation of cartilage and may even promote
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regeneration. There are some adverse side effects associated with HA, but they are
mainly associated with IA administration route. These side effects include muscle pain,
cramping, pain in the injected joint, and swelling of arms and legs. This may make
movement difficult. Overall, HA is a slow acting anti-osteoarthritic agent that can be
used as an anti-inflammatory disease-modifying agent in osteoarthritis (Gupta, 2016;
Gupta et al, 2019a, b).
Astaxanthin (AXT) is a xanthophyll carotenoid that is present in many microalgae
and yeasts. AXT possesses strong antioxidant activity because it neutralizes singlets of
oxygen, scavenges free radicals, inhibits lipid peroxidation, enhances immune system
function, and regulates gene expression. AXT also contributes to glucose metabolism and
decreases lipid accumulation in the liver (Gupta, 2016). Although AXT does not have
any direct links to managing or treating osteoarthritis, it does have many health benefits
that contribute to its use as a supplement. AXT can be used for neuroprotection by
reducing oxidative stress, suppressing expression of inflammatory cytokines, protecting
gastric mucosal linings by stimulating the anti-oxidative mechanism, and by boosting the
immune system. There have not been any side effects reported from use of AXT as a
dietary supplement (Gupta, 2016).
Boswellia serrata, commonly called Indian Frankincense, is a plant that is native
to India and its extract has many health benefits. Boswellic acids (alpha- and betaboswellic acids) are the main component of B. serrata extract. These are organic acids
that consist of a pentacyclic triterpene, a carboxyl group, and at least one other functional
group. Acetyl-keto-beta-boswellic acid (AKBA) contributes most to health benefits and
is present in concentrations of 2-3% of the extract. Boswellic acids have been effective in
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treatments for ulcerative colitis, chemically induced hepatic damage, bronchial asthma,
and other diseases such as osteoarthritis. Acetyl-boswellic acids have exhibited antiinflammatory properties by inhibiting leukotriene synthesis. In some studies, 30% AKBA
provided improvement in joint mobility and comfort in as little as one week (Gupta,
2016).
Green lipped mussel (GLM), Perna canaliculus, is a nutraceutical that is rich in
glycosaminoglycans (GAGs), omega-3 fatty acids, and eicosatetraenoic acid (ETA).
GAGs play an important role in treatment of osteoarthritis as they exert antiinflammatory activities and lubricate joints. ETA also plays a role as it acts as a dual
inhibitor of arachidonic acid oxygenation by COX and lipoxygenase pathways. Use of
GLM has a similar mechanism of action as NSAIDs without adverse side effects. GLM is
a gastroprotective agent and does not affect platelet aggregation. This suggests that ETA
may be selective in only blocking COX-2 while sparing COX-1. There have been no
reported adverse side effects from administration of GLM (Gupta et al, 2019a).
Iron transport tocopheryl polyethylene glycol succinate (ITPGS) exerts several
biological and pharmacological actions (antioxidative, anti-inflammatory, and
immunomodulatory) through multiple mechanisms. ITPGS in Flex Choice, by serving as
bioenhancer, might have improved the absorption and bioavailability of ingredients that
have anti-osteoarthritic properties (Srivastava et al., 2019).
Theoretical Framework
At the base of this theoretical framework is knowledge that there is no known
cure for osteoarthritis. Management practices are the only way to keep affected animals
comfortable and these practices include medications, nutraceuticals, weight management,
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and surgery. With this knowledge, several researchers have set out to try and find new
medications, procedures, and nutraceuticals that will provide animals utmost comfort and
relief from pain.
Nutraceuticals are becoming more and more popular for use in veterinary
medicine to help alleviate signs and symptoms of common problems, including
osteoarthritis. New nutraceuticals are being discovered and tested by researchers on a
regular basis. Flex Choice is a new nutraceutical that was studied as a part of this thesis
study in hopes of finding a new product to help with signs and symptoms associated with
osteoarthritis.
By providing more than one option to manage osteoarthritis, owners will have a
chance to choose which product or procedure that will fit best with their budget and
lifestyle. Medications are an option and relieve symptoms while nutraceuticals have been
shown to provide joints with ingredients needed to prevent further damage. Surgery is an
option, although expensive, if medications or nutraceuticals are not effective or an
underlying issue is causing osteoarthritis.
Summary
This review of literature described many methods that provide pain management
for dogs affected by osteoarthritis. There is no cure for this debilitating disease, but there
are steps that can be taken to minimize pain. Owners can choose to put their dogs on
medication to alleviate pain, try administering a nutraceutical to help with signs and
symptoms, use weight management and physical therapy to help prevent further damage,
or surgery. Out of these options, nutraceuticals are popular as there are new ones put on
the market all the time. According to literature, there are already many nutraceuticals
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available today, but researchers are trying and testing new compounds and combining
compounds in hopes of finding one that is even better and has less long-term effects than
the ones before. This will give owners options to try different formulas to see what works
best for their dog. The purpose of this study was to test the efficacy and safety of a new
nutraceutical, Flex Choice, in osteoarthritic dogs.
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Chapter III: Methodology

Introduction
The purpose of this study was to observe and analyze effects of Flex Choice
(provided by Vets Plus, Inc. of Menomonie, WI) on moderately osteoarthritic dogs over a
150-day period. The study was designed to examine whether or not Flex Choice would
alleviate some of the pain associated with arthritis. This study was also conducted to
determine if any adverse effects occur in liver, kidney, or heart function due to
administration of Flex Choice. Data was collected through subjective observations,
including limb manipulation, physical exertion and overall pain levels and vital signs and
blood serum chemistries. Objectives of this study were as follows:
1. Determine if Flex Choice decreases pain and inflammation caused by arthritis
based on subjective data, such as overall pain, pain during limb manipulation, and
pain after physical exertion.
2. Determine if Flex Choice may increase flexibility and range of motion in affected
joints.
3. Determine safety of Flex Choice by observing overall health, such as heart rate,
respiration rate, temperature, and liver, kidney, and heart function.
4. Evaluate before and after radiographs to determine if affected joints exhibited
improvements.
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Population and Sample Selection
This study was composed of five moderately osteoarthritic dogs that were
selected based on limitations stated in Chapter I, such as weight and level of arthritis.
Sources used to obtain dogs included flyers posted around Murray, KY, Humane Society
of Calloway County, posts published on social media websites such as Facebook, and
flyers sent to faculty and students of Murray State University. Limitations on weight
reduced possible candidates as most interest came from owners of 70+ pound dogs.
Population owners consisted of students and faculty of Murray State University. Owners
volunteered their dogs by signing a consent form consenting the use of their dog,
administering Flex Choice as directed, and meeting with the researcher every 30 days.
This form is located in Appendix B. This selection was purposive and dependent on
owners’ willingness to provide dogs. All five canines were used for duration of the study.
Context of the Study
Study location remained consistent throughout the entire 150 days. Owners
brought their dogs to Carmen Pavilion at Murray State University each month. Carmen
Pavilion provided a neutral location for evaluation and had all amenities necessary for
proper evaluations. Carmen Pavilion Laboratories provided ample room to perform
physical examinations and pain evaluations as well as centrifuge blood samples. Long
hallways located inside provided ample room for physical exertion, and radiograph
equipment was available in a nearby suite of rooms. Weight in pounds was obtained
through use of an electronic scale located just outside the radiology suite. Research was
performed during normal business hours without interruption to scheduled classes.
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Research Design
Time series design is best suited to represent data within this study. All 5 dogs
were included in the treated group and baseline values collected on Day 0 were used as
controls. Dogs received Flex Choice soft chews orally twice daily. Subjective and
objective data were collected on each dog starting with baseline values on Day 0 and
ending on Day 150 with sample collections every 30 days in between. Due to some
scheduling conflicts, some collections were not obtained exactly 30 days apart. Table 1
below illustrates this study’s design.
Table 1: Simple Time Series Design
Date

12/4
Day
0

Treated Obs

30
1/7
Days
Day
30

30
2/7
Days
Day
60

30
3/7
Days
Day
90

30
4/2
Days
Day
120

30
5/6
Days
Day
150

Tx

Tx

Tx

Tx

Tx

Obs

Obs

Obs

Obs

Obs

Obs (Observation)
Tx (Treated)
Data Collection Methods
All data were collected from each of five canines every 30 days for the entire
study duration, a total of 150 days. Dogs in this study were assessed using six different
methods of subjective and objective measurements: pain assessment, physical
examination, blood chemistry, complete blood counts, erythrocyte sedimentation rate,
and radiography. Owners also received a questionnaire to fill out monthly to assess their
dogs pain levels at home. This form is located in Appendix C. Physical exams and pain
assessments were conducted by the researcher on Day 0 and every 30 days during study
duration. See Appendix D for researcher physical exam and pain assessment forms.
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Subjective Data
There were three main scales used to observe pain in arthritic canines:
1. Overall pain was observed on a scale of 1-10 with 1 equaling slight pain and 10
equaling severe and constant pain. Evaluations for overall pain included gait
quality, rising from a sitting or lying position, and lowering into a sitting or lying
position. Owner evaluations were also taken into consideration.
2. Pain during limb manipulation was observed on a scale of 0-4 with a 2-2.5
indicating moderate arthritis. Pain was assessed based on vocalization, body
posture, resistance, flexibility, and range of motion.
3. Pain after physical exertion was observed on a scale of 0-4 with 2-2.5 equaling
moderate arthritis. Pain was assessed based on vocalization, body posture,
flexibility, resistance, and range of motion after 2 minutes of jogging. Canines
were evaluated for evidence of lameness during and after exercise.
Objective Data
Objective data were recorded during physical examination on Day 0 and every 30
days until Day 150. Heart rate and respiration rate were observed using a stethoscope.
Results were recorded in beats per minute. Body temperature was recorded using a digital
rectal thermometer set to degrees Fahrenheit. Body weight was measured using an
electronic scale and recorded in pounds. Radiographs were taken on Days 0 and 150 to
determine if administration of Flex Choice may reverse some arthritic changes in joints.
Blood Collection
Blood samples were collected from canine research subjects using jugular or
cephalic veins with a 20-gauge needle and a 5cc syringe. Samples were then placed into a
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3.5 ml serum separator tube and a 2 ml EDTA tube. Serum separator tubes were allowed
to clot for 20 minutes and then were centrifuged for ten minutes. Serum was then
removed from the clot and placed in a 2 ml red top tube using a pipette. Samples were
then refrigerated until transport to Murray State University Breathitt Veterinary Center
Diagnostic Laboratory. Ms. Jean Miller of the clinical pathology department at Breathitt
analyzed serum for kidney, liver, heart and muscle function biomarkers using a Beckman
AU 480 serum analyzer and whole blood was used for an erythrocyte sedimentation rate
(ESR) and complete blood count (CBC) using a Sysmex XT-2000iV. ESR was used to
test for inflammatory biomarkers.
Data Analysis
All data were subjected to Microsoft Excel data analysis. Data were analyzed
using simple paired T-tests. Values from the T-tests with P < 0.05 were considered
statistically significant when compared to Day 0 values. Graphs were also created using
Microsoft Excel.
Reliability and Validity
As with any research study, precautions must be taken in order to ensure
credibility and trustworthiness of collected data and methods of analysis. In this study,
steps were taken to ensure validity. For collection of subjective and objective data, exams
and assessments were performed consistently in manner and order each month. This
improved consistency when data was recorded in numerical form. Radiographs were also
performed using identical techniques to ensure comparisons were accurate when
evaluating joint changes.
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Chapter IV: Results

Overview
All five canines that participated in this study were used in the treatment group
due to low population size selected for this study. Each owner was given 150 days’ worth
of Flex Choice soft chews. Owners were instructed to orally administer one soft chew in
the morning and one soft chew in the evening for 150 days. The researcher evaluated
canine subjects on Days 0, 30, 60, 90, 120, and 150 at Carmen Pavilion at Murray State
University. Each canine was evaluated for overall pain by observing pain from rising
from a sitting or lying position, lowering into a sitting or lying position, overall gait, and
owner’s observation of overall pain. Each canine was also evaluated for pain during limb
manipulation by observing vocalization, flexibility, resistance, and range of motion. Pain
after physical exertion was also evaluated after two minutes of jogging. Radiographs
were performed on days 0 and 150 and then compared to observe any internal changes in
joints. Blood samples were collected on Day 0 and every 30 days for the duration of the
study, and serum samples were analyzed for changes in liver, kidney, and heart and
muscle function.
All data were recorded and statistically analyzed and mean ± standard error of
means were calculated for each parameter on Day 0 and every 30 days thereafter. All
values are shown in Tables 2 through 9. Some values could not be calculated, such as
respiration rates due to panting.
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Oral administration of Flex Choice soft chews led to a significant reduction in
pain in at least one of the final months of treatment and evaluation. Overall pain was
significantly reduced starting on Day 30 (P < 0.05) and pain during limb manipulation
was significantly reduced on Days 30 and 120 (P < 0.05) and pain after physical exertion
was significantly reduced on Days 120 and 150 (P < 0.05). Body weight, temperature,
respiration, and all but one blood serum chemistry analysis showed no statistical
significance. Creatine kinase showed a significant reduction on Days 30 and 150 (P <
0.05) and heart rate showed a significant reduction starting on Day 60 (P < 0.05).
Overall Pain
Overall pain was evaluated in five canines over a period of 150 days. Baseline
values were collected on Day 0 and canines were reevaluated every 30 days for study
duration. Levels of overall pain were observed based on a scale of 1 to 10 with 1
indicating slight pain and 10 indicating severe and constant pain. Canines used in this
study had a baseline value of overall pain ranging from 4 to 6. Determination of pain
levels were observed based on quality of gait, ability to rise from a sitting or lying
position, ability to lower into a sitting or lying position, range of motion, vocalization,
and body posture. Input from owners on monthly questionnaires were also taken into
account as owners saw their dog on a daily basis.
Table 2 shows results from Day 0 through Day 150. Baseline values on Day 0
showed a mean value of 4.6 ± 0.40, indicating pain from moderate arthritis. Overall pain
was significantly reduced (P < 0.05) starting on Day 30 to 3.6 ± 0.40 and continued to
have a significant reduction (P < 0.05) for Days 60, 90, 120, and 150 (3.6 ± 0.60, 3.4 ±
0.51, 3.2 ± 0.49, and 2.4 ± 0.40 respectively) from Day 0.
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Table 2: Effects of Flex Choice on Overall Pain Level in Arthritic Canines
Day
0

Dog

Level

Mean ± SEM
4.6 ± 0.40

Day Dog
90
Bailey
Reecey
Brutus
Goblin
Lucchese

Level

Mean ± SEM
3.4 ± 0.51 *

Bailey
Reecey
Brutus
Goblin
Lucchese

5
4
6
4
4

30

Bailey
Reecey
Brutus
Goblin
Lucchese

3
3
5
3
4

3.6 ± 0.40 *

120

Bailey
Reecey
Brutus
Goblin
Lucchese

3
3
5
2
3

3.2 ± 0.49 *

60

Bailey
Reecey
Brutus
Goblin
Lucchese

3
3
6
3
3

3.6 ± 0.60 *

150

Bailey
Reecey
Brutus
Goblin
Lucchese

2
2
4
2
2

2.4 ± 0.40 *

*Statistically different from the value of Day 0 (P < 0.05)

3
4
5
3
2
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Pain During Limb Manipulation
Pain during limb manipulation was evaluated in five canines over a period of 150
days. Baseline values were collected on Day 0 and canines were reevaluated every 30
days for study duration. Levels of pain were observed on a scale of 0 to 4 with 0
indicating no pain and 4 indicating severe and constant pain. Moderate arthritic canines
would exhibit a 2 to 2.5 on this scale. Each limb was assessed in standing recumbency
while simultaneously observing vocalization, body posture, stiffness/resistance, integrity,
and crepitus in the joints.
Table 3 shows results of pain during limb manipulation from Day 0 to Day 150.
Baseline values on Day 0 show a mean value of 2.0 ± 0.00. Pain during limb
manipulation showed a significant reduction (P < 0.05) in pain to 1.6 ± 0.10 on Day 30
and again on Day 120 to 1.3 ± 0.12 compared to Day 0.
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Table 3: Effects of Flex Choice on Pain from Limb Manipulation in Arthritic Canines
Day

Dog

Level

Mean ± SEM

Day Dog

Level

Mean ± SEM

0

Bailey
Reecey
Brutus
Goblin
Lucchese

2
2
2
2
2

2.0 ± 0.00

90

Bailey
Reecey
Brutus
Goblin
Lucchese

2
2
2
2
1

1.8 ± 0.20

30

Bailey
Reecey
Brutus
Goblin
Lucchese

1.5
1.5
2
1.5
1.5

1.6 ± 0.10 *

120

Bailey
Reecey
Brutus
Goblin
Lucchese

1.5
1
1.5
1
1.5

1.3 ± 0.12 *

60

Bailey
Reecey
Brutus
Goblin
Lucchese

2
1
2
1.5
1

1.5 ± 0.22

150

Bailey
Reecey
Brutus
Goblin
Lucchese

2
1
2
1
1

1.4 ± 0.24

*Statistically different from the value of Day 0 (P < 0.05)
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Pain After Physical Exertion
Pain after physical exertion was observed in five canines starting on Day 0 until
Day 150. Baseline values were collected on Day 0 and canines were reevaluated every 30
days for the study duration. Pain was observed on a scale of 0 to 4 with 0 indicating no
pain and 4 indicating severe and constant pain. Moderately arthritic canines will exhibit a
2 to 2.5 on this scale. All five dogs were assessed for pain after limb manipulation based
on vocalization, body posture, flexibility, resistance, and range of motion after 2 minutes
of jogging. Canines were also observed for evidence of lameness and exercise
intolerance.
Table 4 shows results of pain after physical exertion from Day 0 to Day 150.
Baseline values on Day 0 exhibited a mean value of 2.0 ± 0.00. Evaluation of pain after
physical exertion resulted in statistically significant reduction (P < 0.05) in pain to 1.2 ±
0.12 on Day 120 and again on Day 150 to 1.2 ± 0.25 compared to values on Day 0.
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Table 4: Effects of Flex Choice on Pain after Physical Exertion in Arthritic Canines
Day

Dog

Level

Mean ± SEM

Day Dog

Level

Mean ± SEM

0

Bailey
Reecey
Brutus
Goblin
Lucchese

2
2
2
2
2

2.0 ± 0.00

90

Bailey
Reecey
Brutus
Goblin
Lucchese

2
2
2
1.5
1

1.7 ± 0.20

30

Bailey
Reecey
Brutus
Goblin
Lucchese

2
2
2.5
2
2

2.1 ± 0.10

120

Bailey
Reecey
Brutus
Goblin
Lucchese

1
1
1.5
1.5
1

1.2 ± 0.12 *

60

Bailey
Reecey
Brutus
Goblin
Lucchese

2
1.5
2.5
1.5
1.5

1.8 ± 0.20

150

Bailey
Reecey
Brutus
Goblin
Lucchese

1.5
1
2
1
0.5

1.2 ± 0.25 *

*Statistically different from the value of Day 0 (P < 0.05)
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Effects of Flex Choice on Body Weight, Heart Rate, Respiration Rate, Temperature,
and Biological Parameters in Serum.
Body weight, heart rate, respiration rate, temperature and biological parameters in
serum were evaluated in all five canines starting with baseline values on Day 0 and
reevaluated every 30 days thereafter for study duration.
Table 5 presents results of body weight in pounds for all five canines participating
in this study. Body weight was recorded using an electronic scale located near the
radiology suite in Carmen Pavilion. There were some fluctuations in weight, including
some that went outside limitations of this study. Body weights were recorded in lbs
(mean ± SEM). Mean value for Day 0 was 52.4 ± 5.71 and Day 150 was 52.6 ± 6.57. No
significant differences (P > 0.05) were observed in canine weight throughout study
duration.
Table 6 presents results of heart rate in beats per minutes of five canine
participants. Heart rate was observed using a stethoscope early in data collection process
and values were recorded. The researcher attempted to keep canines as calm as possible
to get an accurate recording. Some fluctuations were present due to canine excitement
and nervousness. Mean value on Day 0 was 132.8 ± 11.55 with a significant difference (P
< 0.05) observed starting on Day 60 (88.4 ± 7.33) and continued to have a significant
reduction on Days 90, 120, and 150 (109.6 ± 15.88, 107.2 ± 10.84, and 112.8 ± 13.05
respectively) compared to Day 0. This statistical significance could be due to many
factors including level of excitement, level of pain, and nervousness. On Day 0, canines
were very nervous and excited as they were in a new place with a new person performing
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examinations. As each evaluation was complete, canines may have become more familiar
with surroundings and comfortable with the researcher, therefore reducing heart rate.
Table 7 presents results of respiration rate in terms of breaths per minute of all
five canines. Respiration rate was measured using a stethoscope early in data collection
process and values were recorded. The researcher attempted to get an accurate
measurement but panting interfered with valid measurement and values were unable to be
obtained. Therefore, statistical analysis, as well as evaluation of the mean ± SEM, were
not available.
Table 8 presents the results of temperature in terms of degrees Fahrenheit of all
five canines. Temperature was measured by using a digital rectal thermometer and values
were recorded. Mean value on Day 0 was 101.9 ± 0.27 and Day 150 was 101.4 ± 0.24.
No significant differences (P > 0.05) were observed in all canines throughout study
duration.
Table 9 presents data from serum chemistry parameters of all five canine
participants. Blood chemistry parameters included BUN, creatinine, total bilirubin, direct
bilirubin, ALT, AST, and creatine kinase. Blood samples were collected through
venipuncture of either jugular or cephalic vein and serum was separated and transported
to Breathitt Veterinary Center for analysis. There were some slight variations present
possibly due to sample hemolysis and time between collection and analysis. Results of
serum chemistries for BUN, creatinine, total bilirubin, direct bilirubin, ALT, and AST
were not statistically significant (P > 0.05) from values of Day 0 throughout study
duration. Creatine kinase was significantly reduced (P < 0.05) on Day 30 (106.0 ± 19.15)
and Day 150 (112.8 ± 15.81) when compared to Day 0 (165.6 ± 18.17). This reduction
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could be due to delayed sample analysis or individual canine variation as CK has a very
short half-life in the blood. Even with a statistical reduction, the values for CK remained
within reference interval.
Erythrocyte sedimentation (ESR) rates were performed, but values were not
accurate due to delay in analysis from time of sample collection. Those results were
discarded from this study.
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Table 5: Effects of Flex Choice on Body Weight (lb.) of Arthritic Canines
Day Dog
Weight
0
Bailey
63.4
Reecey
56.8
Brutus
64.0
Goblin
41.4
Lucchese 36.4

Mean ± SEM
52.4 ±5.71

Day Dog
90
Bailey
Reecey
Brutus
Goblin
Lucchese

Weight

30

Bailey
Reecey
Brutus
Goblin
Lucchese

63.4
57.2
65.4
42.4
35.6

52.8 ± 5.89

120

Bailey
Reecey
Brutus
Goblin
Lucchese

62.1
60.0
67.0
41.2
34.1

52.9 ± 6.42

60

Bailey
Reecey
Brutus
Goblin
Lucchese

65.6
58.8
66.4
40.0
34.0

53.0 ± 6.72

150

Bailey
Reecey
Brutus
Goblin
Lucchese

60.8
62.8
65.8
39.8
33.8

52.6 ± 6.57

65.6
56.8
68.0
41.0
34.1

No statistically significant differences from the value of Day 0 (P > 0.05)

Mean ± SEM
53.1 ± 6.71
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Table 6: Heart Rate/Min. of Arthritic Canines Treated with Flex Choice
Day Dog

BPM

Mean ± SEM

Day Dog

BPM

Mean ± SEM

0

Bailey
Reecey
Brutus
Goblin
Lucchese

168
108
152
116
120

132.8 ±11.55

90

Bailey
Reecey
Brutus
Goblin
Lucchese

140
80
152
104
72

109.6 ±15.88 *

30

Bailey
Reecey
Brutus
Goblin
Lucchese

120
104
168
116
96

120.8 ±12.55

120

Bailey
Reecey
Brutus
Goblin
Lucchese

144
80
116
96
100

107.2 ±10.84 *

60

Bailey
Reecey
Brutus
Goblin
Lucchese

102
80
84
108
68

88.4 ± 7.33 *

150

Bailey
Reecey
Brutus
Goblin
Lucchese

140
92
148
84
100

112.8 ±13.05 *

*Statistically different from the value of Day 0 (P < 0.05)
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Table 7: Respiration Rate/Min. of Arthritic Canines Treated with Flex Choice
Day Dog

BPM

Mean ± SEM

Day Dog

BPM

Mean ± SEM

0

Bailey
Reecey
Brutus
Goblin
Lucchese

Pant
24
Pant
Pant
Pant

N/A

90

Bailey
Reecey
Brutus
Goblin
Lucchese

Pant
24
Pant
Pant
Pant

N/A

30

Bailey
Reecey
Brutus
Goblin
Lucchese

Pant
28
Pant
32
Pant

N/A

120

Bailey
Reecey
Brutus
Goblin
Lucchese

Pant
20
Pant
Pant
Pant

N/A

60

Bailey
Reecey
Brutus
Goblin
Lucchese

Pant
28
Pant
32
Pant

N/A

150

Bailey
Reecey
Brutus
Goblin
Lucchese

Pant
40
Pant
Pant
Pant

N/A
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Table 8: Temperature (ºF) of Arthritic Canines Treated with Flex Choice
Day Dog

Mean ± SEM

Day Dog

101.9 ± 0.27

90

Temp
(ºF)
Bailey
102.9
Reecey
101.1
Brutus
101.5
Goblin
102.5
Lucchese 101.2

Mean ± SEM

0

Temp
(ºF)
Bailey
102.9
Reecey
101.6
Brutus
102.2
Goblin
101.4
Lucchese 101.6

101.8 ± 0.36

30

Bailey
Reecey
Brutus
Goblin
Lucchese

104.2
100.5
101.6
101.4
101.6

101.9 ± 0.62

120

Bailey
Reecey
Brutus
Goblin
Lucchese

101.6
101.5
101.5
101.9
101.6

101.6 ± 0.07

60

Bailey
Reecey
Brutus
Goblin
Lucchese

102.6
100.1
102.4
101.3
101.3

101.5 ± 0.45

150

Bailey
Reecey
Brutus
Goblin
Lucchese

102.2
101.1
101.3
101.4
101.2

101.4 ± 0.20

No statistically significant differences from the value of Day 0 (P > 0.05)
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Table 9: Biochemical Parameters of Canines Treated with Flex Choice
Day
0
17.0 ± 3.59

Parameter
30
60
90
BUN
17.4 ± 2.23 15.2 ± 1.98 13.2 ± 4.05
mg/dl
0.90 ± 0.09 0.94 ± 0.06 0.92 ± 0.09 0.90 ± 0.10
CREAT
mg/dl
0.18 ± 0.04 0.14 ± 0.02 0.16 ± 0.24 0.16 ± 0.02
TBIL
mg/dl
0.0 ± 0.00
DBIL
0.0 ± 0.00
0.02 ± 0.02 0.0 ± 0.00
mg/dl
51.6 ±
67.0 ±
ALT
48.2 ± 8.67 63.8 ±
14.61
29.92
30.02
IU/L
26.6 ± 3.61 25.6 ± 2.11 26.8 ± 5.30 26.6 ± 4.06
AST
IU/L
165.6 ±
106.0 ±
132.0 ±
CK
150.6 ±
18.17
19.15 *
38.09
40.27
IU/L
*Statistically different from the value(s) of Day 0 (P < 0.05)

120
16.0 ± 3.05

150
18.2 ± 2.46

0.90 ± 0.11

0.94 ± 0.10

0.14 ± 0.02

0.12 ± 0.02

0.0 ± 0.00

0.0 ± 0.00

85.6 ±
44.55
28.8 ± 6.86

62.8 ±
24.40
23.4 ± 3.23

163.8 ±
56.54

112.8 ±
15.81 *
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Radiographs
Radiographs were taken on Day 0 and Day 150 on all five canines. Care was
taken to attempt to keep technique and positioning the same on each day to improve
comparison. There were no appreciable differences between radiographs from Day 0 to
Day 150 observed on any canine. For proper comparison of joints on radiographs,
positioning of each joint must be practically identical each time and this was not the case
for this study. Canines were unable to be placed in exactly the same position for both
radiograph sessions as different restrainers were used as well as expected movement from
the canines. Technique used was as close to identical as possible, but some adjustments
were made if the radiograph did not turn out appropriately on the first attempt. See
Appendix E for radiographs.
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Chapter V: Discussion and Conclusion

Discussion
Osteoarthritis is a chronic debilitating disease that does not discriminate. It effects
both human and animals, with dogs suffering more often than other species due to
excessive exercise, injury, obesity, genetic disposition, or poor nutrition. Approximately
20 to 25% of the roughly 90 million dogs in the United States have been diagnosed with
arthritis. This leads to researchers testing different remedies of easing pain, improving
joint flexibility, and improving quality of life in those canines affected with this disease.
Lifestyle changes such as weight loss management may help some canines, but others
require medication to reduce the pain associated with arthritis. Non-steroidal antiinflammatories (NSAIDs) are the most commonly prescribed medications for
management of arthritis. These medications, however, are not without risk. Canines may
exhibit decreased appetite, vomiting, gastrointestinal irritation or ulceration, or
hepatopathies with long term use (Merck, 2016). Due to these side effects, researchers
and veterinarians are looking for new methods of pain management.
Nutraceuticals, such as Flex Choice, have become a popular choice among
owners and veterinarians as they provide excellent pain management with little to no side
effects and do not require a prescription. Canine participants in this study were given one
Flex Choice soft chew twice daily for 150 days. Baseline values for overall pain, pain
during limb manipulation, pain after physical exertion, vital signs, weight, and blood
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chemistry parameters were obtained on Day 0 and reevaluated every 30 days for study
duration. Evaluation of overall pain was based on a scale of 1 to 10 and canines were
observed for quality of gait, vocalization, ability to sit, lay down, or stand, and body
posture. Evaluation of pain during limb manipulation was based on a scale of 0 to 4
observing vocalization, body posture, flexibility and range of motion, resistance, and
crepitus of joints. Evaluation of pain after physical exertion was based on a scale of 0 to
4, observing canines for vocalization, lameness, reluctance to move, and overall attitude
after two minutes of jogging. Body weight, heart rate, respiration rate, temperature, and
serum chemistry analysis were evaluated each time to ensure the safety of the canine
throughout the entire duration of the study. Radiographs were taken on Day 0 and Day
150 and then compared to observe if Flex Choice could reduce osteocyte formation in
thoracic and pelvic limbs and hip joints.
Evaluations provided by canine owners were taken into consideration, and the
researcher statistically analyzed data to determine if there was a significant reduction in
pain. Administration of Flex Choice twice daily showed significant reduction in pain
from arthritis over a 150-day period. Several owners commented about how they felt their
dog was feeling better as they noticed a change in physical activity level during the study.
One dog in particular was noted to be able to stand on slick floors again near Day 120 of
the study. Difference in canines were visually noticeable upon study’s conclusion.
Figures in the following section provide graphical evidence of significant differences in
pain throughout the study.
Figure 1 presents overall pain level of canines treated with Flex Choice. There
was a significant reduction in pain by Day 30. Pain levels continued to reduce by Day
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150. All canines benefited from treatment and pain levels were reduced from moderate
pain to mild pain, with some showing more of a difference than others.
Figure 2 presents pain during limb manipulation of canines treated with Flex
Choice. There was a significant reduction in pain observed on Day 30 and Day 120, but
then it increased slightly by Day 150.
Figure 3 presents pain after physical exertion in treated canines. There was a
significant reduction in pain by Day 120 and again on Day 150. Owners noticed a
difference in their dog’s activity level around Day 90 and no comments about decreased
activity were made at study’s conclusion on Day 150.
Lateral radiographs of elbows, shoulders, and stifles as well as ventral dorsal
radiographs of hips were obtained on Day 0 and Day 150 so comparison could be made.
Radiograph quality was dependent on x-ray machine settings and movement of canines.
Steps were taken to attempt consistent quality, but technique and views varied slightly
from Day 0 to Day 150. There were no appreciable differences between Day 0 and Day
150 radiographs.
Physical examinations and blood collections were performed each month during
study duration to ensure safety of Flex Choice. Serum samples were transported to
Breathitt Veterinary Center for analysis. No significant differences overall were observed
in canine serum chemistry values except for CK. CK was significantly reduced on Day
30 and Day 150. This could be due to time from sample collection to analysis. One
canine had elevated BUN values as a baseline at Day 0 of study, but level returned within
reference intervals by Day 150. ALT level was elevated at Day 150 for this same canine.
Body weight, heart rate, respiration rate, and temperature were also evaluated for
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significant differences. Body weight did fluctuate slightly throughout study duration, but
no significant differences were observed. Temperature remained steady throughout study
duration. Heart rate seemed to lower as the study progressed, with a significant reduction
starting on Day 60 and continued to be reduced for Days 90, 120, and 150. This could be
due to canines becoming familiar with surroundings where research took place or reduced
anxiety due to anticipation of treats. Respiration rate fluctuated throughout the study, but
all canines except one were panting during each evaluation. There were no complaints
from owners about loss of appetite, vomiting, diarrhea, or overall negative effects.
Figure 1

*

*

*
*

*Statistically different based on value of Day 0 (P < 0.05)
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Figure 2

*
*

*Statistically different based on value of Day 0 (P < 0.05)
Figure 3

*

*Statistically significant difference from value of Day 0 (P < 0.05)

*
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Conclusion
Results presented for overall pain, pain during limb manipulation, and pain after
physical exertion concluded that administration of Flex Choice soft chews twice daily
significantly reduced pain and inflammation associated with canine arthritis. Although
there was no control group to compare results to, comparisons were made using baseline
values from Day 0. Through physical examination, pain level analysis, and serum
chemistry analysis, Flex Choice has been proven as an effective and safer alternative to
conventional pharmaceuticals commonly used for canine arthritis.
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Appendix A: Pictures of Canine Participants

Bailey

Reecey

Brutus

Goblin

Lucchese
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Appendix B: Owner Consent Form
Owner’s Names: ____________________________________________________
Address: __________________________________________________________
Phone: ____________________________ Alternate Phone: _________________
Canine’s Name: ____________________________________________________
Breed: _____________________________________Age: ___________________

As the owner or authorized agent of the above animal, I give consent for the use of this
animal in the research project of Rachael Webber. The study is outlined as follows: To
observe the effects of this joint supplement on moderately arthritic canines that are not
currently receiving treatment. I understand that participation is voluntary and will
continue for a period of 5 months (150 days). During the 150 days, I am responsible for
giving the canine oral soft chew daily throughout the entire time period. Other
responsibilities will include completion of monthly questionnaires and monthly meetings
with Rachael Webber, who will perform physical observations and collect blood samples.
These meetings will occur on Day 0, Day 30, Day 60, Day 90, Day 120, and Day 150 of
the study. I also consent to withdraw all other arthritis medications the canine may be
receiving throughout the duration of the study. Other medications, such as heartworm
and other parasite control and prevention, can still be administered.

Owner Signature: ___________________________________________________
Date: _____________________________________________________________

Researcher Signature: ________________________________________________
Date: _____________________________________________________________
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Appendix C: Owner Questionnaire
Animal Name: ___________________________________
Owner Name: ____________________________________
1) On a scale of 1-10 (10 being most painful), rank your pets current pain: ____
Please use the following scale to answer question 2-9:
0=no pain
1=mild pain
2=moderate pain
3=severe pain
4=severe and constant pain
2) Does your dog have a difficult time raising his/her limbs? ______
3) Does your dog experience stiffness in the limbs after extended periods of standing or
sitting? ______
4) Does your dog express or whimpers in pain when limbs are manipulated? ______
5) Is your dog tender when touched in the hip/rear area? _____
6) Does your dog experience difficulty going up or downs stairs? _____
7) Is your dog more stiff/painful during times of cold weather? _____
8) Does your dog experience lameness after physical exertion (i.e., walks, running,
playing)? _____
9) Does your dog have difficulty jumping on to furniture, cars, or other objects? ____
Please Answer Yes or No for Questions 10-13:
10) Does your dog whimper, growl, snap, or any other negative outrages when touched?
_____
12) Has your dog been diagnosed with being overweight by a veterinarian? _____
13) Has your dog been diagnosed by a licensed veterinarian with arthritis? ______
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Appendix D: Researchers Forms
Patient Name: __________________
Owner Name: ___________________
Date of Observation: ______________
Weight: ________________
Heart Rate: _____________
Respiration Rate: ________
Temperature: ____________

Right Front Leg:

Left Front Leg:

Right Rear Leg:

Left Rear Leg:

Vocalization:

Condition after 3 minutes of physical exertion:
Extra Information:
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Evaluation Date: ____________
Overall perceived pain level:
1=No pain evident during exam
5=Moderate pain evident
10=Severe and constant pain evident

3

4

5

6

7

8

9

10

Pain while rising from a sitting position 1 2

3

4

5

6

7

8

9

10

Pain while rising from a lying position

1 2

3

4

5

6

7

8

9

10

Pain while lowering body into sitting
or lying positions

1 2

3

4

5

6

7

8

9

10

2

3

4

Pain during limb manipulation
0
0=No pain evident
1=Mild pain evident
2=Moderate pain evident
3=Severe pain evident
4=Severe and constant pain evident

1

1

2

Apparent lameness after 3-minute physical exertion

0

1

2

3

4

Apparent pain after 3-minute physical exertion

0

1

2

3

4
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Appendix E: Radiographs
Radiographs of Bailey

Day 0: Right Lateral view of Thoracic Limbs

Day 0: Right Lateral view of Stifles

Day 150: Right Lateral view of Thoracic Limbs

Day 150: Right Lateral view of Stifles
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Day 0: VD view of Hips

Day 150: VD view of Hips
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Radiographs of Brutus

Day 0: Right Lateral view of Elbows

Day 150: Right Lateral view of Elbows

Day 0: Left Lateral view of Stifles

Day 150: Left Lateral view of Stifles
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Day 0: VD view of Hips

Day 150: VD view of Hips
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Radiographs of Goblin

Day 0: Left Lateral view of Thoracic Limbs

Day 150: Left Lateral view of Thoracic Limbs
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Day 0: VD view of Hips

Day 150: VD view of Hips
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Radiographs of Lucchese

Day 0: Left Lateral view of Elbows

Day 150: Left Lateral view of Elbows
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Day 0: VD view of Hips

Day 150: VD view of Hips
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Radiographs of Reecey

Day 0: Left Lateral view of Thoracic Limbs

Day 0: Right Lateral view of Stifles

Day 150: Left Lateral View of Thoracic Limbs

Day 150: Right Lateral view of Stifles
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Day 0: VD view of Hips

Day 150: VD view of Hips
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Appendix F: IACUC Approval
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